Literature DB >> 30633816

Cholemic Nephropathy Causes Acute Kidney Injury and Is Accompanied by Loss of Aquaporin 2 in Collecting Ducts.

Jan Hinrich Bräsen1, Young-Seon Mederacke2, Jessica Schmitz1, Kateryna Diahovets1, Abedalrazag Khalifa1, Björn Hartleben1, Fermín Person3, Thorsten Wiech3, Eric Steenbergen4, Anika Großhennig5, Michael P Manns2, Roland Schmitt6, Ingmar Mederacke2.   

Abstract

Impairment of renal function often occurs in patients with liver disease. Hepatorenal syndrome is a significant cause of acute kidney injury (AKI) in patients with cirrhosis (HRS-AKI, type 1). Causes of non-HRS-AKI include cholemic nephropathy (CN), a disease that is characterized by intratubular bile casts and tubular injury. As data on patients with CN are obtained primarily from case reports or autopsy studies, we aimed to investigate the frequency and clinical course of CN. We identified 149 patients who underwent kidney biopsy between 2000 and 2016 at the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School. Of these, 79 had a history of liver disease and deterioration of renal function. When applying recent European Association for the Study of the Liver criteria, 45 of 79 patients (57%) presented with AKI, whereas 34 patients (43%) had chronic kidney disease (CKD). Renal biopsy revealed the diagnosis of CN in 8 of 45 patients with AKI (17.8%), whereas none of the patients with CKD was diagnosed with CN. Univariate analysis identified serum bilirubin, alkaline phosphatase, and urinary bilirubin and urobilinogen as predictive factors for the diagnosis of CN. Histological analysis of AKI patients with normal bilirubin, elevated bilirubin, and the diagnosis of CN revealed loss of aquaporin 2 (AQP2) expression in collecting ducts in patients with elevated bilirubin and CN. Biopsy-related complications requiring medical intervention occurred in 4 of 79 patients (5.1%).
Conclusion: CN is a common finding in patients with liver disease, AKI, and highly elevated bilirubin. Loss of AQP2 in AKI patients with elevated bilirubin and CN might be the result of toxic effects of cholestasis and in part be responsible for the impairment of renal function.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30633816     DOI: 10.1002/hep.30499

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Inflammation and Cell Death During Cholestasis: The Evolving Role of Bile Acids.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Gene Expr       Date:  2019-06-28

2.  Bile Acids Are Important Contributors to AKI Associated with Liver Disease: PRO.

Authors:  Peter Fickert; Alexander R Rosenkranz
Journal:  Kidney360       Date:  2021-05-03

3.  Renal tubular injury in hyperbilirubinemia: Bile cast nephropathy.

Authors:  Xun Zhao; Ruiyao Huang; Philip Wong; Pierre-Oliver Fiset; Marc Deschênes
Journal:  Can Liver J       Date:  2021-08-09

4.  The activation of nuclear factor-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling blunts cholestasis-induced liver and kidney injury.

Authors:  Khadijeh Mousavi; Hossein Niknahad; Huifeng Li; Zhipeng Jia; Ram Kumar Manthari; Yangfei Zhao; Xiong Shi; Yuanyu Chen; Asrin Ahmadi; Negar Azarpira; Bahman Khalvati; Mohammad Mehdi Ommati; Reza Heidari
Journal:  Toxicol Res (Camb)       Date:  2021-08-04       Impact factor: 2.680

Review 5.  The Role of Bile Acids in the Human Body and in the Development of Diseases.

Authors:  Yulia Shulpekova; Maria Zharkova; Pyotr Tkachenko; Igor Tikhonov; Alexander Stepanov; Alexandra Synitsyna; Alexander Izotov; Tatyana Butkova; Nadezhda Shulpekova; Natalia Lapina; Vladimir Nechaev; Svetlana Kardasheva; Alexey Okhlobystin; Vladimir Ivashkin
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

Review 6.  Bile Cast Nephropathy: A Comprehensive Review.

Authors:  Manoj R Somagutta; Molly S Jain; Maria Kezia Lourdes Pormento; Siva K Pendyala; Narayana Reddy Bathula; Nagendrababu Jarapala; Ashwini Mahadevaiah; Nayana Sasidharan; Mohamed A Gad; Greta Mahmutaj; Namrata Hange
Journal:  Cureus       Date:  2022-03-29

7.  Silymarin mitigates bile duct obstruction-induced cholemic nephropathy.

Authors:  Mohammad Mehdi Ommati; Omid Farshad; Negar Azarpira; Elmira Ghazanfari; Hossein Niknahad; Reza Heidari
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-04       Impact factor: 3.000

8.  Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury.

Authors:  Roula Sasso; Ahmad Abou Yassine; Liliane Deeb
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

Review 9.  Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.

Authors:  Songtao Liu; Qinghua Meng; Yuan Xu; Jianxin Zhou
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-09-25

Review 10.  Recent advances in the understanding and management of hepatorenal syndrome.

Authors:  Benedikt Simbrunner; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  Fac Rev       Date:  2021-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.